HHI therapy appeared to upregulate MHC class I expression and increase infiltrating immune cells (CD8+, CD4+, HLA-DR-class II+ mononuclear cells, and CD68+ macrophages) at the cancer site. This evidence concerns the gene CD68 and cancer.